What exactly changed in the GILD analyst rating on March 06, 2026?

Citigroup maintained a **Buy** rating on Gilead Sciences, Inc. (GILD) on **March 06, 2026**. The update left the recommendation unchanged and included no new price target.

Does the update include a new GILD price target?

No. The Citigroup record and related coverage did not publish a new **GILD price target**. Media coverage referenced Yeztugo script growth but no fresh valuation was released.

How should investors use the maintained Buy in their strategy?

Treat the maintained **Buy** as continued analyst confidence, not an immediate buy signal. Combine this with earnings, script trends, and pipeline data before changing allocations.

Where can I read the analyst note and company coverage?

The StreetInsider report referenced BofA’s reiterated Buy and Yeztugo script acceleration [source](https://www.streetinsider.com/Analyst+Comments/BofA+Securities+Reiterates+Buy+Rating+on+Gilead+Sciences+%28GILD%29+as+weekly+Yeztugo+scripts+accelerate/26122498.html). For broader analyst summaries see

What is Meyka AI’s current view on GILD?

Meyka AI rates GILD with a grade of **B+**. This reflects relative benchmark performance, sector trends, financial growth, key metrics, and analyst consensus.

Analyst Ratings

Citigroup Maintains Buy on GILD (Gilead Sciences, Inc.) March 2026

ByHuzaifa Zahoor March 9, 2026March 9, 2026

Citigroup maintained a Buy rating on Gilead Sciences, Inc. (GILD) on March 06, 2026 and left the recommendation unchanged. The GILD analyst rating appears alongside market commentary noting accelerating weekly Yeztugo scripts, a point highlighted in media coverage. StreetInsider reported that BofA also reiterated a Buy in related coverage, though no new price target was published. The firm-level action and sector notes matter for investors watching Gilead’s infectious disease and oncology revenue streams and near-term sentiment.